Compounds > perhexiline

perhexiline and toremifene

perhexiline has been researched along with toremifene in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	1 (20.00)	2.80

Authors

Authors	Studies
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Byun, SY; Choi, I; Jeon, S; Kim, S; Ko, M; Lee, J; Park, S; Shum, D	1
Cammue, BP; Chaltin, P; De Brucker, K; Delattin, N; Marchand, A; Meert, E; Thevissen, K; Vandamme, K	1

Reviews

1 review(s) available for perhexiline and toremifene

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

4 other study(ies) available for perhexiline and toremifene

Article	Year
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. Antimicrobial agents and chemotherapy, 2020, 06-23, Volume: 64, Issue:7 Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells	2020
Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms. The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:4 Topics: Amphotericin B; Androstenes; Animals; Antifungal Agents; Biofilms; Caenorhabditis elegans; Candida albicans; Caspofungin; Drug Repositioning; Drug Synergism; Echinocandins; Lipopeptides; Microbial Sensitivity Tests; Osteoblasts; Perhexiline; Toremifene	2014